Global corrective action plan required; Growth delayed by 2 years DRL received 3 warning letters from the USFDA for API plants Srikakulam (Vizag), Miryalaguda, Telangana and an oncology plant at Duvvada (Vizag). The action follows the earlier inspection of these sites in Nov'14, Jan'15 and Feb'15 respectively. While Srikakulam F483 was a concern, the issuance of the warning letter for the other 2 facilities is a negative surprise. The USFDA has mandated for a global corrective action plan with third party verification across facilities, which can significantly delay resolution. While approved products are not currently impacted, we assess...